MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
19.38
+0.46
+2.43%
After Hours: 19.34 -0.04 -0.21% 19:57 04/02 EDT
OPEN
18.40
PREV CLOSE
18.92
HIGH
19.85
LOW
18.40
VOLUME
3.08M
TURNOVER
--
52 WEEK HIGH
36.91
52 WEEK LOW
13.83
MARKET CAP
15.03B
P/E (TTM)
-13.4220
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
TipRanks · 1d ago
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors
TipRanks · 4d ago
Weekly Report: what happened at SMMT last week (0323-0327)?
Weekly Report · 5d ago
Barclays Remains a Hold on Summit Therapeutics (SMMT)
TipRanks · 5d ago
Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases
Reuters · 03/27 16:25
Summit Therapeutics publishes HARMONi-2 ivonescimab vs pembrolizumab quality-of-life presentation; median PFS rises to 11.1 months due to HR 0.51
Reuters · 03/27 16:25
Summit Therapeutics releases HARMONi Phase 3 ivonescimab HRQoL presentation; trial enrollment totals 438 patients
Reuters · 03/27 16:25
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/27 15:36
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.